Business Wire

ZYXEL-COMMUNICATIONS

13.1.2021 07:02:39 CET | Business Wire | Press release

Share
Telenor Norway selects Zyxel Communications for its 5G roll-out

Telenor Norway has selected Zyxel Communications’ 5G NR Fixed Wireless Access outdoor router – NR 7101 to roll out the world’s fastest and biggest 5G FWA.

As the first mobile operator of 5G in Scandinavia, Telenor is modernizing its existing network infrastructure with plans to offer nationwide 5G access by 2024. The company introduced wireless broadband in May 2019. Later that year, Telenor Norway partnered with Ericsson to modernize and deliver its nationwide 5G radio access network.

The selection of Zyxel Communications marks yet another important milestone for Telenor’s work in upgrading customers to 5G.

Zyxel’s 5G NR FWA outdoor router – NR 7101 uses modern antenna technology for Telenor to offer high-speed wireless connectivity. The company cited Zyxel’s innovative technology, effective local presence and collaborative approach as key reasons for its decision.

“Telenor is dedicated to providing Individual customers and businesses with faster speeds and more bandwidth,” said Camilla Amundsen, CMO, Fixed and TV of Telenor Norway. “Customers connect more innovative technologies and smart devices to their respective networks and expect maximum coverage everywhere. FWA supports the increasing number of individuals and families working and learning from home; where platforms such as video conferences, interactive learning, cloud-based enterprise solutions, TV streaming and online gaming demand significant broadband access. FWA is therefore an important part of Telenor’s network modernization and our partnership with Zyxel makes this possible.”

“Zyxel is helping Telenor reach an additional level of service for customers throughout Norway and oversee the world’s fastest, largest rollout of 5G FWA,” Amundsen added.

With Zyxel’s NR7101 outdoor router, Telenor also will provide customers with a smooth transition to 5G, while offering them access to its 4G network. This allows the provider to maximize speeds, regardless of network, and leverage its existing infrastructure investments throughout the rollout of 5G.

“Telenor is an industry pioneer in 5G and is at the forefront of deploying modern, next-generation networks for customers,” said Karsten Gewecke, SVP, Head of EMEA Regional BU at Zyxel Communications. “With our state-of-the-art 5G NR FWA technology, we’re playing a major role in delivering superior wireless access to customers everywhere throughout Norway.”

“Combined with short delivery time, high speeds and increased reliability, FWA is an attractive solution for many customers – not only existing DSL customers,” Karsten Gewecke concludes.

Telenor currently offers 5G in the following areas: Trondheim, Bergen, Kongsberg, Elverum, Bodø, Askvoll, Telenor Fornebu, Kvitfjell, Longyearbyen, Herøya, Frøya and Spikersuppa in Oslo. The service provider also is actively deploying 5G in Ålesund, Kristiansand, Fredrikstad, Tromsø and Bodø. In addition, Telenor plans to make 5G available nationwide in Norway by 2024. Likewise, after December 2020, all new FWA-customers are offered Zyxel’s 5G-ready FWA outdoor router, which ensures a smooth transition for subscribers not yet covered by 5G.

About Telenor Norway

Telenor Norway AS is the country's largest provider of telecommunications and digital services. Its infrastructure is the foundation of the digitization of Norway with world-class coverage and speeds. Its services and products contribute to increased productivity and provide access to all digital content. Its safety and emergency response organization works 24/7 to keep customers safe, and Telenor Norway takes special social responsibility to create safety for children and young people online.

About Zyxel Communications

Zyxel Communications delivers technological innovations and has connected the world to the Internet for more than 30 years. Whether it’s a matter of establishing access through fixed or mobile broadband solutions, Zyxel Communications offers a comprehensive and flexible portfolio of products that’s keeping service providers ahead of the competition.

Read the full Telenor customer story here .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release

News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release

Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye